October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.1 This huge cost has largely been attributed to rising clinical development costs and high failure rates of drugs tested in Phase 2 studies or later. On average, only 14% of drugs in development make it to market2 and the average time to move a drug from Phase 1 to approval is about 10 years.3 In addition, failure can also happen in the drug manufacturing process or the industrialization of the drug delivery device.
At Portal, we are acutely aware of the costs, risks and uncertainty involved with drug development and delivery. We know that introducing a novel needle-free drug delivery device into the market may appear to increase the technical risks. So, we have taken deliberate steps to identify and “de-risk” the process of partnering with us.
The development of new drugs is inherently risky. Portal Instruments is transforming the drug delivery landscape by responding to a real patient unmet need, backed with robust science. Needle-based self-injections are a real struggle for patients at a time when they are vulnerable and affected by sometimes a life-threatening disease. We can change that and turn the self-injection challenge into an opportunity to assist patients on their road to improve their health. Portal’s vision for a needle-free world is enabled by our maniacal obsession to systematically and rigorously identify, break down, and mitigate risks. This has been the key to make our pharmaceutical partners feel confident about working with us.
April 2021 - In the US, approximately 12% of women age 15 to 44 have trouble getting pregnant or carrying a pregnancy to term.¹ To honor National Infertility Week we sat down with Myra, an infertility nurse to talk about the hardships and joys associated with infertility treatment.
May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
October 2024 - At the Partnership Opportunities in Drug Delivery (PODD) conference, Robert Hidalgo showcased Portal Instrument's latest advancements on its reusable, electro-mechanical drug delivery platform.
Please fill out the details below and we will get back to you shortly.